Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TRAVOPROST

Form:

4 of 4 products shown

All strengths: Limited Use — Reason for Use code 171, 172, 387 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 171, 172, 387 required
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (S01E, S01EE) — coverage varies; not interchangeable

  • Bimatoprost (Lumigan): limited Use 171, 172, 387, Not a benefit
  • Latanoprost (Xalatan): limited Use 171, 172, 387
  • Latanoprostene bunod (Vyzulta): limited Use 171, 172, 387
  • Acetazolamide (Acetazolamide): general benefit, Not a benefit
  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit

10 more in the class list below

IZBA · DIN 02457997 · 0.003% · Oph Sol (with Preservative)

Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
IZBA · DIN 02457997 Manufacturer: Novartis Pharma Canada Inc.; listing date 2019-04-30 Health Canada: Marketed since 2018-04-03 · brand IZBA · ATC S01EE04 TRAVOPROST · form Solution · route Ophthalmic · ingredients TRAVOPROST 0.003 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

IZBA: Formulary list price $3.9400/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.9400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94502 · Verify on the e-Formulary ↗ (DIN 02457997)

Source record
DIN 02457997: IZBA Raw flags: sec12=Y, sec3=Y Item: 523600144; group id 643; item number 1620; lccId 00318; manufacturer id NOV Source form: Oph Sol (with Preservative); strength: 0.003% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.9400; ministry $3.9400 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02457997 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94502
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02457997
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Travoprost Z · DIN 02548089 · 0.004% · Oph Sol-5mL Pk

Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Travoprost Z · DIN 02548089 Manufacturer: Jamp Pharma Corporation; listing date 2025-07-31 Health Canada: Marketed since 2025-05-20 · brand JAMP TRAVOPROST Z · ATC S01EE04 TRAVOPROST · form Solution · route Ophthalmic · ingredients TRAVOPROST 0.004 %/W/V · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Travoprost Z: Formulary list price $28.7600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $28.7600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103698 · Verify on the e-Formulary ↗ (DIN 02548089)

Source record
DIN 02548089: Jamp Travoprost Z Raw flags: sec12=Y, sec3=Y Item: 523600119; group id 644; item number 1621; lccId 00094; manufacturer id JPC Source form: Oph Sol-5mL Pk; strength: 0.004% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $28.7600; ministry $28.7600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02548089 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103698
Interchangeable products
Sandoz Travoprost · DIN 02413167 · $28.7600 Travatan Z · DIN 09857332 · $28.7600
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02548089
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Travoprost · DIN 02413167 · 0.004% · Oph Sol-5mL Pk

Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Travoprost · DIN 02413167 Manufacturer: Sandoz Canada Inc.; listing date 2014-10-29 Health Canada: Marketed since 2014-08-15 · brand SANDOZ TRAVOPROST · ATC S01EE04 TRAVOPROST · form Solution · route Ophthalmic · ingredients TRAVOPROST 0.004 %/W/V · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Travoprost: Formulary list price $28.7600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $28.7600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89784 · Verify on the e-Formulary ↗ (DIN 02413167)

Source record
DIN 02413167: Sandoz Travoprost Raw flags: sec12=Y, sec3=Y Item: 523600119; group id 644; item number 1621; lccId 00094; manufacturer id SDZ Source form: Oph Sol-5mL Pk; strength: 0.004% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $28.7600; ministry $28.7600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02413167 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89784
Interchangeable products
Jamp Travoprost Z · DIN 02548089 · $28.7600 Travatan Z · DIN 09857332 · $28.7600
Shortage status: active shortage (reported 2026-07-13, estimated to end 2026-09-18, last updated 2026-09-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02413167
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Travatan Z · PIN 09857332 · 0.004% · Oph Sol-5mL Pk

Limited Use — Reason for Use code 171, 172, 387 requiredOntario PIN; no Health Canada record under this code
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02318008 (Marketed, 2018-02-01) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80351

Check Health Canada brand DIN
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Travatan Z · DIN 09857332 Manufacturer: Novartis Pharma Canada Inc.; listing date 2009-08-18 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02318008 (Marketed, 2018-02-01) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80351
Check this DIN again

Ministry pays: $28.7600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857332)

Source record
DIN 09857332: Travatan Z Raw flags: sec12=Y, sec3=Y Item: 523600119; group id 644; item number 1621; lccId 00094; manufacturer id NOV Source form: Oph Sol-5mL Pk; strength: 0.004% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $58.9600; ministry $28.7600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857332 Health Canada record for this brand: DIN 02318008 (Marketed, 2018-02-01) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80351
Interchangeable products
Jamp Travoprost Z · DIN 02548089 · $28.7600 Sandoz Travoprost · DIN 02413167 · $28.7600
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857332
Shortage record checked 2026-09-13T08:10:21.292534+00:00

TIMOLOL MALEATE & TRAVOPROST

Form:

4 of 4 products shown

3 Limited Use · 1 not a benefit

Other products in the same Health Canada class (S01E, S01EE) — coverage varies; not interchangeable

  • Bimatoprost (Lumigan): limited Use 171, 172, 387, Not a benefit
  • Latanoprost (Xalatan): limited Use 171, 172, 387
  • Latanoprostene bunod (Vyzulta): limited Use 171, 172, 387
  • Acetazolamide (Acetazolamide): general benefit, Not a benefit
  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit

10 more in the class list below

Apo-Travoprost-Timop · DIN 02415305 · 0.5% & 0.004% · Oph Sol

Limited Use — Reason for Use code 310, 393 required; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health CanadaMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada
Write on scriptLU code 310, 393 (patient must meet the criteria below); DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Apo-Travoprost-Timop · DIN 02415305 Manufacturer: Apotex Inc.; listing date 2019-04-30 Health Canada: Marketed since 2020-03-03 · brand APO-TRAVOPROST-TIMOP PQ · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TRAVOPROST 0.004 %/W/V, TIMOLOL (TIMOLOL MALEATE) 0.5 %/W/V · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Travoprost-Timop: Formulary list price $8.8425/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.8425 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89992 · Verify on the e-Formulary ↗ (DIN 02415305)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02415305). DIN 02415305: Apo-Travoprost-Timop Raw flags: dinStatus=E, sec12=Y, sec3=Y Item: 523600116; group id 642; item number 1618; lccId 00198; manufacturer id APX Source form: Oph Sol; strength: 0.5% & 0.004% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; DIN status E, meaning unconfirmed Source prices (unrounded): $8.8425; ministry $8.8425 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02415305 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89992
Interchangeable products
DuoTrav · DIN 02278251 · not recorded
Shortage status: shortage reported ended 2026-08-28 (report last updated 2026-08-28); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02415305
Shortage record checked 2026-09-13T08:10:21.292534+00:00

DuoTrav · DIN 02278251 · 0.5% & 0.004% · Oph Sol

Listed, not a benefitMarketed · checked 2026-09-02
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
DuoTrav · DIN 02278251 Manufacturer: Alcon Canada Inc.; listing date 2009-01-30 Health Canada: Marketed since 2018-01-19 · brand DUOTRAV PQ · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 %/W/V, TRAVOPROST 0.004 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

DuoTrav: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76384 · Verify on the e-Formulary ↗ (DIN 02278251)

Source record
DIN 02278251: DuoTrav Raw flags: notABenefit=Y, sec3=Y Item: 523600116; group id 642; item number 1618; lccId 00198; manufacturer id ALC Source form: Oph Sol; strength: 0.5% & 0.004% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02278251 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76384
Interchangeable products
Apo-Travoprost-Timop · DIN 02415305 · $8.8425
Shortage status: active shortage (reported 2026-07-02, estimated to end 2026-10-19, last updated 2026-07-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02278251
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Travoprost-Timop PQ · PIN 09857644 · 0.5% & 0.004% · Oph Sol-5mL Pk

Limited Use — Reason for Use code 310, 393 requiredOntario PIN; no Health Canada record under this code
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02415305 (Marketed, 2020-03-03) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89992

Check Health Canada brand DIN
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Apo-Travoprost-Timop PQ · DIN 09857644 Manufacturer: Apotex Inc.; listing date 2020-06-30 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02415305 (Marketed, 2020-03-03) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89992
Check this DIN again

Apo-Travoprost-Timop PQ: Formulary list price $44.2125/unit (unit not stated in source; not the patient's cost)

Ministry pays: $44.2125 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857644)

Source record
DIN 09857644: Apo-Travoprost-Timop PQ Raw flags: sec12=Y, sec3=Y Item: 523600139; group id 642; item number 1619; lccId 00198; manufacturer id APX Source form: Oph Sol-5mL Pk; strength: 0.5% & 0.004% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $44.2125; ministry $44.2125 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857644 Health Canada record for this brand: DIN 02415305 (Marketed, 2020-03-03) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89992 Therapeutic Notes (formulary) This product is stable for 120 days after opening. Please refer to the product monograph for more information.
Interchangeable products
DuoTrav PQ · DIN 09857513 · $44.2125
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857644
Shortage record checked 2026-09-13T08:10:21.292534+00:00

DuoTrav PQ · PIN 09857513 · 0.5% & 0.004% · Oph Sol-5mL Pk

Limited Use — Reason for Use code 310, 393 requiredOntario PIN; no Health Canada record under this code
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02278251 (Marketed, 2018-01-19) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76384

Check Health Canada brand DIN
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Duotrav PQ (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
DuoTrav PQ · DIN 09857513 Manufacturer: Novartis Pharma Canada Inc.; listing date 2014-11-27 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02278251 (Marketed, 2018-01-19) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76384
Check this DIN again

Ministry pays: $44.2125 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857513)

Source record
DIN 09857513: DuoTrav PQ Raw flags: sec12=Y, sec3=Y Item: 523600139; group id 642; item number 1619; lccId 00198; manufacturer id NOV Source form: Oph Sol-5mL Pk; strength: 0.5% & 0.004% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $56.7000; ministry $44.2125 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857513 Health Canada record for this brand: DIN 02278251 (Marketed, 2018-01-19) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76384 Therapeutic Notes (formulary) This product is stable for 120 days after opening. Please refer to the product monograph for more information.
Interchangeable products
Apo-Travoprost-Timop PQ · DIN 09857644 · $44.2125
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857513
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

LATANOPROST

· 9 products · Limited Use, codes 171, 172, 387 · strengths: 0.005% · Oph Sol-2.5mL Pk

LATANOPROSTENE BUNOD

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 0.024%w/v · Oph Sol

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp

BRINZOLAMIDE & BRIMONIDINE TARTRATE

· 1 products · Limited Use, codes 466, 393 · strengths: 1.0% & 0.2% · Oph Susp-10mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 19 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: intraocular pressure
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. BRINZOLAMIDE & BRIMONIDINE TARTRATE · Limited Use, codes 466, 393 • the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction AND when the use of SIMBRINZA is considered appropriate. PM: https://pdf.hres.ca/dpd_pm/00068869.PDF; date DEC 23, 2022; DIN 02435411; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Sandoz Travoprost is indicated for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension. Pediatrics (< 18 years of age): The safety and effectiveness of Sandoz Travoprost have not been established in pediatric patients, and its use is not recommended in these patients. https://pdf.hres.ca/dpd_pm/00051001.PDF PM date: May 7, 2019 Source product: SANDOZ TRAVOPROST; DIN 02413167; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS DUOTRAV® PQ (travoprost and timolol) is indicated for the reduction of elevated IOP in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins, or other IOP lowering agents AND when the use of DUOTRAV PQ (the fixed combination drug) is considered appropriate. DUOTRAV PQ should not be used to initiate therapy. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatics (>65 years of age): No overall differences in safety or effectiveness have been observed between elderly and other adult patients. https://pdf.hres.ca/dpd_pm/00059283.PDF PM date: December 17, 2020 Source product: DUOTRAV PQ; DIN 02278251; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

IZBA · DIN 02457997 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02457997

Check this DIN again

Sandoz Travoprost · DIN 02413167 Shortage status: active shortage (reported 2026-07-13, estimated to end 2026-09-18, last updated 2026-09-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02413167

Check this DIN again

Apo-Travoprost-Timop · DIN 02415305 Shortage status: shortage reported ended 2026-08-28 (report last updated 2026-08-28); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02415305

Check this DIN again

DuoTrav · DIN 02278251 Shortage status: active shortage (reported 2026-07-02, estimated to end 2026-10-19, last updated 2026-07-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02278251

Check this DIN again

Other review policies

For DuoTrav: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026